DENTSPLY SIRONA Inc. $XRAY Position Increased by Quantinno Capital Management LP

Quantinno Capital Management LP increased its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 53.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,079,189 shares of the medical instruments supplier’s stock after acquiring an additional 374,755 shares during the quarter. Quantinno Capital Management LP’s holdings in DENTSPLY SIRONA were worth $12,519,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of XRAY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in DENTSPLY SIRONA during the 1st quarter worth $26,000. Eurizon Capital SGR S.p.A. acquired a new position in DENTSPLY SIRONA in the fourth quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd raised its position in shares of DENTSPLY SIRONA by 337.9% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 2,122 shares during the period. Farther Finance Advisors LLC raised its holdings in DENTSPLY SIRONA by 119.1% during the 4th quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock worth $43,000 after buying an additional 2,051 shares during the period. Finally, Performa Ltd US LLC raised its holdings in shares of DENTSPLY SIRONA by 116.1% during the fourth quarter. Performa Ltd US LLC now owns 4,250 shares of the medical instruments supplier’s stock valued at $49,000 after acquiring an additional 2,283 shares during the period. 95.70% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently weighed in on XRAY. Mizuho dropped their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Weiss Ratings downgraded shares of DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Piper Sandler boosted their target price on DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Wednesday, July 29th. UBS Group cut their target price on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Citigroup started coverage on DENTSPLY SIRONA in a research report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price objective for the company. Three research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $13.46.

DENTSPLY SIRONA Trading Up 5.7%

XRAY stock opened at $14.13 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52. The business’s 50 day moving average is $11.52 and its 200-day moving average is $11.86. DENTSPLY SIRONA Inc. has a 1-year low of $9.40 and a 1-year high of $14.86. The firm has a market cap of $2.83 billion, a P/E ratio of -4.49, a P/E/G ratio of 1.59 and a beta of 0.85.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). The firm had revenue of $880.00 million for the quarter, compared to the consensus estimate of $841.80 million. DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.DENTSPLY SIRONA’s quarterly revenue was up .1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.43 earnings per share. Equities analysts anticipate that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Brian T. Gladden acquired 9,985 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were purchased at an average price of $10.02 per share, with a total value of $100,049.70. Following the acquisition, the director directly owned 61,849 shares in the company, valued at $619,726.98. The trade was a 19.25% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Brian P. Mckeon bought 10,000 shares of DENTSPLY SIRONA stock in a transaction dated Friday, June 12th. The shares were bought at an average price of $10.12 per share, for a total transaction of $101,200.00. Following the completion of the transaction, the director directly owned 10,000 shares of the company’s stock, valued at $101,200. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 35,160 shares of company stock worth $351,179 in the last 90 days. Corporate insiders own 0.46% of the company’s stock.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.